Cohance Lifesciences Schedules Board Meeting on 6th Nov'26 for Q2/H1 Results
Cohance Lifesciences Ltd 路 Intimation 路 06 Nov 2026, 5:30 am
Cohance Lifesciences Schedules Board Meeting on 6th Nov'26 for Q2/H1 Results Cohance Lifesciences Limited has scheduled its Board of Directors meeting for 6th Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for dealing in the company's securities, which has been closed for designated persons and their immediate relatives since 28th Sep'26, will remain shut until 9th Nov'26.
Original exchange filing (PDF)
More announcements from Cohance Lifesciences Ltd
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings .... 路 12 Nov 2026
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 12 Nov 2026
- Investors Meet 路 11 Nov 2026
- Transcript of Con call 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings Pvt Ltd & Others 路 11 Nov 2026
- Investor Presentation 路 07 Nov 2026
- Update on USFDA inspection at Pashamylaram Manufacturing facility. 路 07 Nov 2026
